High CD8(+) and absence of Foxp3(+) T lymphocytes infiltration in gallbladder tumors correlate with prolonged patients survival
Artículo
Open/ Download
Access note
Acceso abierto
Publication date
2018Metadata
Show full item record
Cómo citar
Fluxá Rojas, Paula
Cómo citar
High CD8(+) and absence of Foxp3(+) T lymphocytes infiltration in gallbladder tumors correlate with prolonged patients survival
Author
Abstract
Background: Gallbladder cancer (GBC), although infrequent in industrialized countries, has high incidence rates in certain world regions, being a leading cause of death among elderly Chilean women. Surgery is the only effective treatment, and a five-year survival rate of advanced-stage patients is less than 10%. Hence, exploring immunotherapy is relevant, although GBC immunogenicity is poorly understood. This study examined the relationship between the host immune response and GBC patient survival based on the presence of tumor-infiltrating lymphocytes at different disease stages.
Methods: Tumor tissues from 80 GBC patients were analyzed by immunohistochemistry for the presence of CD3(+), CD4(+), CD8(+), and Foxp3(+) T cell populations, and the results were associated with clinical stage and patient survival.
Results: The majority of tumor samples showed CD3(+) T cell infiltration, which correlated with better prognosis, particularly in advanced disease stages. CD8(+), but not CD4(+), T cell infiltration correlated with improved survival, particularly in advanced disease stages. Interestingly, a < 1 CD4(+)/CD8(+) T cell ratio was related with increased survival. Additionally, the presence of Foxp3(+) T cells correlated with decreased patient survival, whereas a <= 1 Foxp3(+)/CD8(+) T cell ratio was associated with improved patient survival.
Conclusions: Depending on the disease stage, the presence of CD8(+) and absence of Foxp3(+) T cell populations in tumor tissues correlated with improved GBC patient survival, and thus represent potential markers for prognosis and management of advanced disease, and supports testing of immunotherapy.
Patrocinador
National Fund for Scientific and Technological Development (FONDECYT)
1171213
11160380
Fund for the Promotion of Scientific and Technological Development (FONDEF)
ID16i10148
Millennium Institute on Immunology and Immunotherapy (MIII)
P09/016-F
National Commission for Scientific and Technological Research (CONICYT)-PCHA/Doctorado Nacional
21130465
CONICYT-PAI/TESIS DOCTORADO SECTOR PRODUCTIVO
7815110008
FONDECYT POSTDOCTORADO
3170917
Indexation
Artículo de publicación ISI
Quote Item
BMC Cancer (2018) 18: 243
Collections
The following license files are associated with this item: